UnitedHealth ’s Optum Rx To Coax Patients To Less Pricey Biosimilars Of Abbvie’s Humira

UnitedHealth Group ’s OptumRx will put biosimilar versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as the brand” on the PBM’s formulary in 2023.

Source: Forbes.com Healthcare News - November 15, 2022 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma Source Type: news